The Filing Desk

Caris Life Sciences

CAI · Nasdaq · Health Care · Financials, fiscal 2023 to 2025

CAI · Last close · November 19, 2026
$18.54
Value Caris Life Sciences yourself

Caris Life Sciences' revenue rose 97.0% to $812 million in fiscal 2025. Its operating margin was 5.6%, up from −62.4% a year earlier. Free cash flow was $67 million. It paid out $0 million in dividends and buybacks, 0% of free cash flow. The diluted share count rose 371.0%.

CARIS LIFE SCIENCES, INC. Latest fiscal year ended December 31, 2025 10-K filed March 3, 2026 · 0002019410-26-000016 Updated
Revenue
$812M
97.0%
Operating margin
5.6%
67.9 pts
Net income
−$68M
 
Free cash flow
$67M
 
Return on equity
—
 
Market cap
$5.5B
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

What Caris Life Sciences does

Caris Life Sciences runs laboratory tests that read the genetic makeup of a patient's cancer, with the aim of helping doctors choose treatments. It is also a data company: it uses artificial intelligence on its large set of genetic and clinical data. It was founded in 2008, and as of December 31, 2025, it had sequenced over 1,000,000 cases.

Its Molecular Intelligence product line focuses on oncology and has three platforms: MI Profile (tissue-based tests), Caris Assure (blood-based tests) and the Precision Whole Genome Platform. It serves clinical, academic and drug-company (biopharma) customers. Doctors order its tests for patients. Biopharma and research partners also use its data and bioinformatics services to look for drug targets.

The company says its current revenue comes mainly from its tissue-based profiling solution. It received FDA approval in November 2024 for MI Cancer Seek, a test it launched in January 2025 and expects to drive growth. It expects to launch whole genome sequencing solutions in 2026.

Its biggest risks, as it describes them

  • Competition in a precision medicine field that changes quickly.
  • Losses since it was founded, and possibly not reaching profit.
  • Needing coverage and adequate payment from Medicare and other insurers for its tests.
  • Relying on tissue-based profiling for most revenue, and on doctors adopting MI Cancer Seek.
  • Relying on a few or sole suppliers for sequencers and lab supplies.
From Caris Life Sciences's annual report on Form 10-K, filed March 3, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Caris Life Sciences lost money in fiscal 2025: a net loss of $68 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY23FY24FY25
Cash and short-term investments—66799
Debt incl. finance leases—374379
Net debt (negative means net cash)—307−420
Net debt to EBITDA——−6.2x
Debt to equity——0.7x
Interest coverage−10.1x−5.1x0.8x
Current ratio—1.3x7.8x
Quick ratio—1.3x7.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Caris Life Sciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Caris Life Sciences says to expect

  • Full year 2026: revenue and test volumeCaris Life Sciences now expects full year 2026 revenue to be in the range of $1.04 to $1.05 billion, representing growth of 28% to 29% compared to full year 2025 and reaffirms its guidance for clinical therapy selection volume growth of approximately 20% compared to full year 2025.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 4, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $1.5 million of Caris Life Sciences shares on the open market, and 4 insiders sold $28.9 million, $1.7 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 22, 2026John Russel DentonSee RemarksSold7,500$31.82$238,650Form 4
Sep 17, 2026Brian J BrilleSee Remarks, DirectorSold400,000$30.33$12.1 millionForm 4
Sep 4, 2026David Baxley SpetzlerPresidentSold119,212$24.76$3.0 millionForm 4
Sep 3, 2026David Baxley SpetzlerPresidentSold478,000$24.86$11.9 millionForm 4
May 15, 2026Jon HalbertDirectorBought68,000$14.56$990,080Form 4
May 11, 2026Jeff L VacircaDirectorBought31,050$16.15$501,457Form 4
Dec 11, 2025Luke Thomas PowerSee RemarksSold plan62,250$26.57$1.7 millionForm 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25
Piotroski F-score——
Rule of 40−26.9%105.2%
Altman Z''−31.74−0.93
Accruals ratio—−20.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25
Net income is positive—Fail
Cash from operations is positiveFailPass
Return on assets rose——
Cash from operations exceeds net incomePassPass
Debt fell relative to assets——
Current ratio rose—Pass
Share count didn't riseFailFail
Gross margin rose——
Revenue rose relative to assets——
F-score——
Companies that report no gross profit are scored on the other eight.

Compare

Put Caris Life Sciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Caris Life SciencesFY2597.0%5.6%8.2%—−6.2x—
Myriad GeneticsFY25−1.6%−47.0%−1.7%−62.6%—5Compare
NeoGenomics LaboratoriesFY2510.1%−15.9%−3.0%−8.8%—5Compare
Pennant GroupFY2536.3%5.5%3.8%9.3%2.6x5Compare
CorVelFY267.0%—11.5%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY23FY24FY25
Income statement
Revenue306412812
Revenue growth—34.7%97.0%
Gross profit———
Research and development117114102
Operating income−320−25745
Net income−341−282−68
Diluted EPS (US$)−13.24−10.66−3.22
Diluted shares (millions)3536167
Cash flow
Cash from operations−276−24583
Capital expenditure22816
Free cash flow−298−25467
Dividends paid000
Share buybacks000
Acquisitions000
Stock-based compensation151970
Balance sheet at fiscal year end
Cash and short-term investments—66799
Debt incl. finance leases—374379
Total assets—3441,126
Total liabilities—621548
Shareholders' equity−2,145−2,499577
Margins and ratios
Gross margin———
Operating margin−104.4%−62.4%5.6%
Net margin−111.5%−68.4%−8.4%
Free cash flow margin−97.5%−61.5%8.2%
Rule of 40 (growth + FCF margin)—−26.9%105.2%
Return on capital———
Return on equity———
Return on assets——−9.3%
Net debt to EBITDA——−6.2x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Caris Life Sciences' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Caris Life Sciences.